Form 4: Recursion Pharma CFO Sells Shares

Recursion Pharmaceuticals' Chief Financial Officer, Ben R. Taylor, reported the disposition of 15,031 shares of Class A Common Stock through tax withholding and a pre-planned sale.

Summary

• Ben R. Taylor, Chief Financial Officer of Recursion Pharmaceuticals, Inc. (RXRX), reported two dispositions of Class A Common Stock.
• On March 16, 2026, 7,075 shares were withheld by the Issuer to satisfy tax withholding obligations in connection with the net settlement of restricted stock units, at a price of $3.42 per share.
• On March 17, 2026, 7,956 shares were sold at a price of $3.39 per share.
• The sale transaction on March 17, 2026, was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Taylor on September 30, 2025.
• Following these transactions, Mr. Taylor beneficially owns 1,180,318 shares of Class A Common Stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative due to the insider selling, even though a portion was for tax withholding and the sale was pre-planned under a 10b5-1 plan. Insider sales, regardless of reason, can sometimes be perceived as a lack of confidence.

Positives

• The tax withholding transaction is a routine event for the net settlement of restricted stock units and is not typically indicative of negative sentiment.
• The sale transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting it was part of a personal financial strategy rather than a reaction to new, non-public information.

Negatives

• An officer selling shares, even under a 10b5-1 plan, can be perceived negatively by some investors as it reduces their direct stake in the company.
• The total disposition of 15,031 shares represents a reduction in the CFO's direct ownership.

Risks

• Investor perception risk: Insider selling, even if pre-planned, can sometimes be misinterpreted by the market as a lack of confidence, potentially leading to downward pressure on the stock price.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales under Rule 10b5-1 plans, are common occurrences across all industries, including biotechnology. While a sale by a Chief Financial Officer might draw attention, the pre-planned nature of the transaction suggests it is likely for personal financial planning, such as diversification or liquidity, rather than a reflection of immediate concerns about Recursion Pharmaceuticals' operational performance or prospects. Such transactions are generally viewed as less impactful than unplanned, open-market sales.

Stakeholder Impact

• Shareholders: May view the insider sale with caution, potentially interpreting it as a signal, despite the 10b5-1 plan.

Key Dates

Recommendation

While the disposition of shares by a key executive like the CFO can be a cause for concern, the fact that a significant portion was for tax obligations and the open market sale was conducted under a pre-arranged 10b5-1 plan mitigates the immediate negative signal. This suggests a planned financial move rather than a reaction to new adverse company-specific information. Investors should monitor future insider activity and company performance, but this specific filing alone does not warrant a 'sell' recommendation, nor does it provide a strong 'buy' signal.

Keywords

Recursion Pharmaceuticals, RXRX, Insider Trading, Form 4, Stock Sale, CFO, Ben Taylor, 10b5-1 Plan, Biotechnology, Pharmaceuticals